Xolremdi (mavorixafor, oral CXCR4 antagonist for WHIM syndrome)
Named-patient access overview. Xolremdi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Xolremdi
Xolremdi (mavorixafor) is an oral, once-daily small-molecule antagonist of the CXCR4 chemokine receptor, developed by X4 Pharmaceuticals. It is approved by the US FDA for patients aged 12 years and older with WHIM syndrome, the rare inherited primary immunodeficiency defined by warts, hypogammaglobulinemia, recurrent infections, and myelokathexis (the retention of mature neutrophils in the bone marrow).
The biology of WHIM syndrome is driven by gain-of-function mutations in CXCR4 that trap mature neutrophils and lymphocytes in the bone marrow instead of releasing them into the peripheral circulation. By antagonizing CXCR4, mavorixafor blocks that retention signal and mobilizes neutrophils and lymphocytes into the bloodstream, addressing the underlying mechanism of the recurrent infections that define the disease.
For international patients, Xolremdi is sourced by Reserve Meds from a DSCSA-compliant US specialty wholesaler with full serial traceability and may be accessible via Named Patient Program or personal-import pathways depending on destination country.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Xolremdi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Xolremdi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Xolremdi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Xolremdi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Xolremdi
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.